Mistletoe Therapy in Primary and Recurrent Inoperable Pancreatic Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

290

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2022

Conditions
Pancreatic Cancer
Interventions
DRUG

Mistletoe extract (Iscador Qu)

1ml subcutaneous injection 3 times/week, dose escalation 0,01mg - 20mg

DRUG

Placebo

1ml subcutaneous injection 3 times/week

Trial Locations (1)

14186

Kathrin Wode, Stockholm

All Listed Sponsors
collaborator

University of Witten/Herdecke

OTHER

collaborator

Karolinska Institutet

OTHER

collaborator

Regional Cancer Centre Stockholm Gotland

OTHER

collaborator

Stiftelsen Konung Gustaf V:s Jubileumsfond för cancerforskning

UNKNOWN

collaborator

Signe & Ane Gyllenbergs Stiftelse

UNKNOWN

collaborator

Ekhagastiftelsen

OTHER

collaborator

Dagmar Ferbs Minnesfond

UNKNOWN

collaborator

Cancerforskningsfonden i Norrland

UNKNOWN

collaborator

Immunpathologisches Labor, University Tübingen

UNKNOWN

collaborator

The Sjöberg Foundation

UNKNOWN

lead

Karolinska University Hospital

OTHER

NCT02948309 - Mistletoe Therapy in Primary and Recurrent Inoperable Pancreatic Cancer | Biotech Hunter | Biotech Hunter